Background & Aims: We performed a meta-analysis of individual patient data from 11 randomized controlled trials comparing corticosteroids, pentoxifylline, or their combination in patients with severe alcoholic hepatitis. We compared the effects of the treatments on survival for 28 days or 6 months, and response to treatment based on the Lille model.
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INTRODUCTION
Patients with severe alcoholic hepatitis (AH) constitute a subgroup in which development of new strategies or new molecules are required to improve short-(28-day) or medium-term (3-6-month) mortality. AASLD in 2010 1 and EASL in 2012 2 have recommended treatment with pentoxifylline and corticosteroids for severe AH to reduce 28-day mortality. Only one randomized controlled trial (RCT) comparing pentoxifylline to placebo was available at the time of these recommendations 3 . Five meta-analysis of the literature evaluating the therapeutic benefit of corticosteroids have yielded inconsistent results, 3 concluded that there was a survival benefit in patients with severe AH 4-6 whereas 2 others questioned their efficacy in AH regardless of disease severity 7, 8 . Alternatively, the last meta-analysis using individual data from five randomized controlled trials observed that corticosteroids significantly improve 28-day survival in patients with severe alcoholic hepatitis 9 . Because of the divergence of the results of these various analyses, some experts still question the efficacy of those molecules.
Within the last decade, 7 head-to-head RCTs [10] [11] [12] [13] [14] [15] [16] published in English have been available. Three RCTs compared corticosteroids versus pentoxifylline and three RCTs a combination of these two agents to either one of them. The last RCT with a 2x2 factorial design and a large sample size 16 concluded that prednisolone reduces the risk of mortality up to 28 days after adjustment for baseline prognostic factors whereas pentoxifylline had no impact on disease outcome.
A recent Bayesian network meta-analysis reported that pentoxifylline and corticosteroids (alone or in combination with pentoxifylline or N-acetylcysteine) can reduce short-term mortality whereas no treatment decreases the risk of medium-term mortality 17 .
The conclusion of this meta-analysis with regard to the effect of pentoxifylline on short-term M A N U S C R I P T
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mortality was different to that drawn from the results of the recent large RCT 16 that showed no significant impact of pentoxifylline on short-term mortality.
To improve the level of evidence and increase the relevance of the statistical analysis,
we performed a new meta-analysis using individual patient data (MIPD) from 11 RCTs testing corticosteroids (CS), pentoxifylline (PTX) or their combination in patients with severe alcoholic hepatitis (Maddrey discriminant function (DF) ≥32). As the primary objective was to assess the short-term (28-day) efficacy of CS, PTX or their combination, only RCTs testing these strategies were considered.
The present MIPD integrates the clinical and biological data of each randomized patient when available. This allows us to evaluate the independent survival impact of each treatment modality after adjustment on classical prognostic factors and to quantify their effect in terms of biological improvement upon therapy. This approach is critical since it has been established that early biological improvement is an important predictor of short-term and medium-term mortality. An early identification of response to therapy can be assessed by the Lille model 18 , which may also be of interest to compare the effect of molecules, as a surrogate endpoint.
The main aims of our MIPD from 2111 patients originating from 11 RCTs published were to compare patients receiving either corticosteroids, or pentoxifylline or their combination to those who did not receive them after adjusting for baseline prognostic factors in terms of: a/ 28-day survival; b ) 6-month survival; c/ response to treatment using the Lille model;
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PATIENTS AND METHODS
Patients
The search strategy was performed by two investigators (PM, AL) with input from study investigators using Medline data base and manual searches with keyword capabilities, for RCTs of pharmacological therapy for severe AH. For RCTs testing corticosteroids, the search strategy started after the previously published MIPD integrating 5 RCTs 9, [19] [20] [21] [22] [23] . Studies were selected if they were randomized, published as full articles in English, had specific data on patients with DF ≥32 or encephalopathy, and if those RCTs compared corticosteroids versus pentoxifylline, one of them versus placebo or therapy without any effect on 28-day mortality, or a combination of these two agents to either one of them. We combined data from the previously published MIPD integrating 5 RCTs 9 and data from 6 RCTs whose principal investigators agreed to participate 3, [12] [13] [14] [15] [16] . The previous MIPD had combined five RCTs comparing corticosteroids to placebo or therapy without any effect on 28-day mortality. The other six RCTs compared pentoxifylline plus corticosteroids versus corticosteroids alone (n=2) 12, 15 , pentoxifylline versus placebo (n=1) 3 , pentoxifylline versus corticosteroids (n=2) 13, 14 and pentoxifylline, corticosteroids or their combination in a 2x2 factorial design (n=1) 16 with one group receiving placebo alone, a second group receiving prednisolone alone, a third group receiving pentoxifylline alone, and a fourth group receiving pentoxifylline and prednisolone. Four RCTs testing these treatment modalities were not included for the following reasons: 1) one RCT was published only in an abstract form 24 ; 2) 3 RCTs for which M A N U S C R I P T 26 . Only patients with severe alcoholic hepatitis were included using the definition used in previous MIPD and RCTs (i. e. DF ≥ 32 and/or encephalopathy).
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Statistical analysis
All analyses were conducted according to the intention-to-treat principle by including all randomized patients, irrespective of whether they subsequently received the intended treatment. Main baseline characteristics were described in each trial and in each meta-analysis according to treatment group. Continuous variables were expressed as means (standard deviation) or as medians (interquartile range) in cases of a non-normal distribution.
Categorical variables were expressed as frequencies (percentages). Survival curves were estimated using the Kaplan-Meier method. For each meta-analysis, absolute standardized differences between treatment groups were calculated and values>10% were considered to be a meaningful imbalance. The risk of publication bias cannot be statistically assessed because of the number of trials included per meta-analysis.
In each meta-analysis, the treatment effect on the primary outcome (overall survival at 28 days defined as the period from the first day of assigned treatment to 28 days) was estimated using a Cox proportional hazards regression model including trials as random effect (frailty model). A model with fixed-effects stratified by trial was also used. The proportional hazards assumption was assessed by plotting the scaled Schoenfeld residuals of treatment effect against the rank of survival time 27, 28 . Heterogeneity across trials was examined by the Cochran's Q test and quantified by calculating the I 2 statistics 29 ; Cochran's Q test with a p value <0.10 or I 2 >50% were interpreted as meaningful heterogeneity. Hazard ratio (HRs) and M A N U S C R I P T
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95% confidence intervals (CI) were derived from Cox regression models as relative effect size measures. In case of significant difference, we also calculated the absolute risk difference and the number needed to treat (NNT) from the marginal probabilities using the method described by Austin 30 ; 95%CI were estimated using bootstrap method (2000 bootstrap samples). We tested the interaction between baseline discriminant function and treatment effect sizes by including the corresponding interaction term in Cox regression models. A pre-specified secondary analysis was conducted adjusting for age, baseline discriminant function, creatinine (after log-transformation), and albumin as covariates into the Cox's regression model. To avoid case deletion in primary adjusted analysis due to missing data on baseline covariates, missing data were imputed by multiple imputations (m=10) using regression switching approach (chained equations using all baselines characteristics, death status and the survival times after a logarithmic transformation) with predictive mean matching method for continuous variables, logistic regression model for binary variables, and ordinal logistic regression for ordered categorical variables 31 . Imputation involves filling in the missing values with plausible values and performing the statistical analyses on this completed data set.
The imputation process must be repeated several times and the results of analyses performed on each completed data set are then combined according to rules proposed by Rubin 32 . We also reported complete-cases adjusted analysis as sensitivity analysis. Treatment effects on 6-month mortality were analyzed as a pre-specified secondary endpoint using the same statistical methods as for primary outcome. We have also provided the treatment effects on 3-month mortality as an unplanned analysis.
The response to the assigned treatment assessed with the Lille model, a score ranging from 0 to 1, was a secondary end point. without and with pre-specified confounding factors. Additional adjustment for bilirubin at baseline was done for comparison of changes in bilirubin at 28days. Similar to primary outcome, to avoid case deletion in adjusted analysis due to missing data on baseline covariates, missing data were imputed by multiple imputations using regression switching approach; a sensitivity adjusted analysis were performed on complete cases. The statistical plan was registered on clinicaltrials.gov (NCT02796469) on June 10th 2016, before the analysis.
Statistical testing was done at the two-tailed α level of 0.05. Data were analyzed using SAS software (version 9.4, SAS Institute Inc., Cary, NC, USA).
Role of the funding source M A N U S C R I P T
This study was not supported by any company or grants. The cost was borne by the authors' institutions.
RESULTS
We obtained data for 2111 participants from 11 trials; 6 trials involving 956 participants comparing corticosteroids versus control, 2 trials involving 666 participants comparing corticosteroids versus pentoxifylline, 3 trials involving 886 participants comparing the combination of corticosteroids and pentoxifylline to corticosteroids alone, and 3 trials involving 694 participants comparing pentoxifylline versus control (Supplemental Figure 1 ).
Individual data was not available for one trial included in the meta-analysis comparing corticosteroids versus control 19 ; only mortality information could be extracted from the published manuscript using the method developed by Fine et al. and others 33, 34 . The main baseline characteristics and outcomes (28-day and 6-month mortality, response therapy assessed by Lille model) for each included trial are available in Supplemental Table 1 . The characteristics of the patients from the 4 excluded studies (see Patients for more details) are provided in Supplemental Table 2 . Overall, 1972 (93.4%) of 2111 participants had complete information for primary endpoint and pre-specified confounding factors. Baseline characteristics and Kaplan-Meier survival curves according to treatment groups per metaanalysis are shown in Table 1 and Figure 1 .
28-day mortality (Primary outcome)
Overall, 383 of 2111 patients died within the 28 days following randomization (mortality at 28 days using the Kaplan-Meier method: 18.5%). As shown in Figure In multiple imputation and complete case analyses adjusted for pre-specified confounding factors, the effect of corticosteroids against control remained significant ( Table   2 ). For corticosteroids against pentoxifylline, the corticosteroid effect remained significant in the complete case adjusted analysis (HR, 0.66; 95%CI, 0.43 to 0.98, p=0.04) but not in multiple-imputation adjusted analysis (HR, 0.71; 95%CI, 0.48 to 1.05; p=0.085).
There was no difference in 28-day mortality in meta-analysis comparing the combination of corticosteroids and pentoxifylline versus corticosteroids alone (HR, 0.92; 95%CI, 0.63 to 1.33) or in the meta-analysis comparing pentoxifylline versus controls (HR, 0.91; 95%CI, 0.64 to 1.28). Similar findings were found after the pre-specified adjustment (Table 2 ). However, heterogeneity was apparent in pentoxifylline versus control metaanalysis ( Figure 2 , I 2 =55%, p=0.11). Similar results were found using fixed-effects models (Supplemental Table 3 ).
We tested whether the assigned treatment influenced 28-day mortality according to baseline disease severity. Thus, we tested the interaction between Maddrey's discriminant function (treated as a continuous variable) and treatment group on the main outcome (28-day mortality) in each meta-analysis. We did not find any significant interaction in any of the meta-analyses (p=0.71 in first meta-analysis, p=0.09 in second meta-analysis, p=0.33 in third meta-analysis and p=0.49 in fourth meta-analysis). In addition, we also assessed this interaction treating Maddrey's discriminant function as a binary variable using the 75th M A N U S C R I P T
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percentiles as a cut-off value for the most severely ill patients and confirmed that there was no interaction between disease severity and treatment efficacy (see Supplemental Table 4 ).
6-month mortality
Of the 11 included trials, two trials involving 66 and 50 participants, respectively, with no follow-up information after 30 days, were excluded from the 6-month mortality analysis;
one was included in the first meta-analysis comparing corticosteroids versus controls 20 and the other one in the fourth meta-analysis comparing pentoxifylline versus controls 14 . Overall, 704 of 1995 patients died within the 6 months after randomization (mortality at 6 months using the Kaplan-Meier method: 37.7%). As shown in Figure 3 and Table 3 , there were no significant between group differences in 6-month mortality whatever the meta-analysis.
However, the proportional hazard assumption for the effect of corticosteroids versus controls or pentoxifylline was violated (Supplemental Figure 2) , with a reducing protective HR with follow-up time. In addition, apparent heterogeneity was observed for the first (I 2 =67%, p=0.017) and fourth (I 2 =83%, p=0.017) meta-analysis. Similar results were found using fixedeffects models (Supplemental Table 3 ). We did not find any significant between-group differences in 3-month mortality in any of the meta-analyses in unplanned analyses (see Supplemental Figure 3 and Supplemental Table 5 ).
Pooling arms drawn from trials involving different comparators makes it possible to make indirect comparisons without respecting the methodology of a randomized controlled trial. If we combined the 11 trials together, we could estimate the effect of the combination of corticosteroids and pentoxifylline compared to controls while none of the trials performed this comparison. In addition to previous data, we performed such a pooled analysis with a Cox regression model adjusted for trials and pre-specified confounding variables (age, discriminant function, creatinine and albumin). We observed similar results, once again M A N U S C R I P T
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confirming the effect of corticosteroids compared to controls or pentoxifylline in 28-day mortality and showing the effect of the combination of corticosteroids and pentoxifylline compared to controls see Supplemental Table 6 for numbers and effects at 28 days and Supplemental Table 7 for numbers and effects at 6 months.
Response therapy assessed by Lille model
One of the 11 included trials without individual data involving 71 participants was excluded from the response-to-therapy analysis; this trial was included in the first metaanalysis comparing corticosteroids versus control. Overall, 923 (58.3%) of 1581 patients with available Lille model score were classified as responders to therapy (score <0.45).
On overall patients, regardless of treatment, patients classified as responders had a (complete, partial and null) on overall patients, 28-day survival was significantly different; using null response category as reference, the HR (95% CI) was 0.14 (0.09 to 0.22) for complete response and 0.31 (0.23 to 0.41) for partial response). This difference between the three response groups was also observed in each allocated treatment group (data not shown).
As shown in Figure 4 , corticosteroids were significantly associated with increased There was no evidence of heterogeneity across trials whatever the meta-analysis, except in the fourth meta-analysis (pentoxifylline versus controls) treating response-to-therapy as a continuous outcome (Supplemental Figure 4 , I 2 =64%, p=0.065). Multivariate analysis adjusted for pre-specified confounding factors yielded similar results (Supplemental Tables 8-9 -10). Similar results were found using fixed-effects models (Supplemental Table 11 ).
Regarding one of the planned secondary outcome measurements (i.e. bilirubin at 28 days),
there was a significant amount of missing data (bilirubin at 28 days was only available in 748/2111 patients in the entire cohort, regardless of the trial (35.4%)). However, we have performed this analysis in this small group of patients and show that decrease in bilirubin level at 28 days was higher in patients who received corticosteroids than in those who did not (Supplemental Table 12 ). There was no difference in change in bilirubin levels at 28 days between the two groups in the third meta-analysis (corticosteroids vs.
corticosteroids+pentoxifylline), showing that the addition of pentoxifylline to corticosteroids did not have a pharmacological effect. In the second (corticosteroids vs. pentoxifylline) and fourth meta-analyses (pentoxifylline vs. placebo), data were only available in 94 and 87 patients, respectively. These data should be interpreted with caution due to the amount of missing data.
DISCUSSION
The present MIPD performed using individual data of 11 RCTs showed that patients treated with corticosteroids had higher 28-day survival than patients treated with either placebo/control or pentoxifylline. Pentoxifylline alone or its combination with corticosteroids 
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Future studies design testing drugs to improve liver injury in AH should assess survival in relation to duration of drug exposure in order to avoid the potential bias of analysis of outcome far after the cessation of treatment. We suggest that future studies evaluate 3 or 6 months of drug exposure and consider 3-or 6-month survival as end-points to test the impact of molecules targeting liver injury. We feel that the optimal time point should be 3 months, as alcohol relapse starts around 2-3 months and starts to impact survival between 3 and 6 months 35 .
In the present MIPD, pentoxifylline neither improved short-term survival and nor modified response to therapy. MIPD have a truth survival advantage over than meta-analysis of the literature 36 . The lack of survival impact observed here with pentoxifylline or its combination may appear in contrast to the last meta-analysis of the literature concluding to a potential effect of pentoxifylline on 28-day mortality 17 . However, in this previous metaanalysis, survival benefit of pentoxifylline was observed only in network meta-analysis but not in the analysis based on direct comparison of treatment. As a consequence, the investigators concluded to there was a low quality of evidence supporting the use of pentoxifylline and ranked the probability of its use at 4 in a score ranging from 1, best to 6, worst for treatment in severe alcoholic hepatitis. In the present MIPD, pentoxifylline alone or administered in combination with corticosteroids does not influence outcome. The results from the present MIPD are not in favor of the use of pentoxifylline in severe alcoholic hepatitis when considering the importance of early improvement in short-term outcome.
We analyzed the impact of allocated therapy on medium-term mortality (6-month mortality) and did not observe any differences in survival whatever the allocated therapy. This raises several concerns on the medium or long-term impact of molecules in alcoholic hepatitis. The proportional hazard assumption for the effect of corticosteroids versus controls or pentoxifylline is violated, which may be related to the important discordance of duration of M A N U S C R I P T
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drug exposure (28 days) and length of period of evaluation (6 months). All RCTs were not designed for medium term and none for long-term. Analysis of medium-and long-term data to determine efficacy of a drug given for a short-term period of time (28 days) in patients with severe alcoholic hepatitis is debatable. Indeed, a recent prospective study with sequential assessment of clinical, biological parameters and alcohol consumption showed that short-term and medium-term outcome (before 6 months) is mainly related to the severity of liver injury at baseline and early improvement in hepatic function whereas long-term outcome (after 6 months) is mainly influenced by alcohol consumption and must be analyzed in relation to early improvement in liver injury 35 . Such caution in interpretation of long-term data has been also highlighted in non-hepatic chronic diseases. As an example, a randomized controlled trial
showed that beneficial effect of tight control of blood pressure disappeared during the long term when no strategy to maintain such control was made 37 . Therefore in the setting of alcoholic hepatitis, scientific societies and experts should be very cautious when interpreting long-term data in studies evaluating short-term exposure to therapy in relation to the risk of recurrent alcohol consumption over the time.
In summary, the present MIPD show that corticosteroids improve 28-day survival and response to treatment but this protective HR disappears over 6 months. Such loss of efficacy over the time highlights the urgent need for clinicians to focus on new therapeutic strategies aiming to improve medium-term outcome. All absolute standardized differences (ASD) were <10% except for prothrombin time in meta-analysis n°2 (ASD=15%) and n°4 (ASD=11%), ascites in metaanalysis n°3 (ASD=23%), encephalopathy in meta-anal ysis n°4 (ASD=14%) and ASAT in meta-analysis n°4 (A SD=11%).
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Abbreviations: AST=aspartate aminotransferase; DF=discriminant function; IQR=interquartile range; SD=standard deviation. Hazard ratios (HRs) and their 95% confidence intervals (CIs) were calculated using a Cox's regression model including trials as random effect and prespecified baseline confounding factors (age, discriminant function, creatinine and albumin) as fixed effects. 
Excluding the study by Cabre et al. 19 Combined hazard ratios (HRs) and their 95% confidence intervals (CIs) were calculated using a Cox's regression model including trial as random effect M A N U S C R I P T
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1 Excluding the study by Cabre et al. 19 Combined hazard ratios (HRs) and their 95% confidence intervals (CIs) were calculated using a Cox's regression model including trial as random effect M A N U S C R I P T
Combined hazard ratios (HRs) and their 95% confidence intervals (CIs) were calculated using a generalized linear mixed model (binomial distribution, log link function including trial as random effect M A N U S C R I P T
Supplemental Table 1. Main baseline characteristics and outcomes of each included trial
Mendenhall et al. 21 Ramond et al. 23 Carithers et al. 20 Phillips et al. 22 Cabre et al. 19 Park et al. 
12
Thursz et al. 16 Sidhu et al. 15 Sidhu et al. Hazard ratios (HRs) were estimated from the Cox model including trial as random effect and pre-specified confounding variables (age, baseline DF, creatinine, and albumin) as fixed effects.
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
Supplemental
Supplemental Table 7 . Adjusted treatment effect sizes on 6-month mortality in 9 trials (with 6-month follow-up) pooled together Hazard ratios (HRs) were estimated from the Cox model including trial as random effect and pre-specified confounding variables (age, baseline DF, creatinine, and albumin) as fixed effects Risk ratio (RRs) and their 95% confidence intervals (CIs) were calculated using a generalized linear mixed model (binomial distribution, log link function) including trials as random effect and baseline confounding factors (age, discriminant function, creatinine and albumin) as fixed effects. Common odds ratios (ORs) and theirs 95% confidence intervals (CIs) for improvement in Lille model were calculated using a generalized linear mixed model (multinomial distribution, cumulative logit link function) model including trials as random effect and pre-specified baseline confounding factors (age, discriminant function, creatinine and albumin) as fixed effects.
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Supplemental Cohen' d (standardized difference) and theirs 95% confidence intervals (CIs) were calculated after a logit transformation of Lille model and by using a mixed linear regression model including trials as random effect and pre-specified baseline confounding factors (age, discriminant function, creatinine and albumin) as fixed effects. 
